It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment [REF].
Panitumumab was the first monoclonal antibody to demonstrate the use of KRAS as a predictive biomarker.